Aspirin resistance: Effect of clinical, biochemical and genetic factors

Pharmacology and Therapeutics

Volumn 130, Issue 2, 2011, Pages 213-225

  FitzGerald, Richard ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Anti platelets; Aspirin; Aspirin resistance; Cardiovascular disease; Pharmacogenetics; Platelet function testing

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; IBUPROFEN; VALSARTAN;

BLOOD EXAMINATION; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; GENETIC PREDISPOSITION; HEREDITY; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIGHT TRANSMITTANCE AGGREGOMETRY; LOW DRUG DOSE; PATIENT COMPLIANCE; PHENOTYPE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; TACHYPHYLAXIS; THROMBOCYTE ACTIVATION; URINALYSIS;

ASPIRIN; CARDIOVASCULAR DISEASES; DRUG EVALUATION; DRUG RESISTANCE; HUMANS; MODELS, BIOLOGICAL; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RISK FACTORS;

EID: 79953657561     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2011.01.011     Document Type: Review

References (153)

1. Aggarwal, A., Schneider, D. J., Terrien, E. F., Sobel, B. E., & Dauerman, H. L. (2004). Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am. J. Cardiol. 93(1), 6-9.
2. Andre, P., Nannizzi-Alaimo, L., Prasad, S. K., & Phillips, D. R. (2002). Platelet derived CD40L. The switch-hitting player of cardiovascular disease. Circulation 106(8), 896-899.
3. Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramirez, C., Sabate, M., et al. (2006). Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am. J. Cardiol. 97(1), 38-43.
4. Antithrombotic Trialists' Collaboration (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death. Myocardial infarction and stroke in high risk patients. BMJ 324(7329), 71-86.
5. Aukrust, P., Muller, F., Ueland, T., Berget, T., Aaser, E., et al. (1999). Enhanced levels of soluble and membrane bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocytes and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100(6), 614-620.
6. Becker, D. M., Segal, J., Vaidya, D., Yanek, L. R., Herrera-Galeano, J. E., et al. (2006). Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295(12), 1420-1427.
7. Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., et al. (2008 Oct 16). The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337, a1840, doi:10.1136/bmj.a1840.
8. Belton, O., Byrne, D., Kearney, D., Leahy, A., & Fitzgerald, D. J. (2000). Cycloxygenase-1 and -2 dependent prostacyclin formation in patients with atherosclerosis. Circulation 102(8), 840-845.
9. Bernardo, E., Angiolillo, D. J., Ramirez, C., Cavallari, U., Trabetti, E., et al. (2006). Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. Platelets 17(8), 586-590. (Pubitemid 44837729)
10. Bierend, A., Rau, T., Maas, R., Schwedhelm, E., & Boger, R. H. (2008). P2Y(12) polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. Br. J. Clin. Pharmacol. 65(4), 540-547.
11. Borna, C., Lazarowski, E., van Heusden, C., Ohlin, H., & Erlinge, D. (2005). Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 3(Jul), 10.
12. Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J. T., et al. (2010). Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8), 754-762.
13. Bruno, A., McConnell, J. P., Mansbach, H. H., Cohen, S. N., Tietjen, G. E., Bang, N. U. (2002). Aspirin and urinary 11-dehydrothromboxane in African American stroke patients. Stroke 33(1), 57-60. (Pubitemid 34052185)
14. Bruno, A., McConnell, J. P., Cohen, S. N., Tietjen, G. E., Wallis, R. A., et al. (2004). Serial 11- dehydrothromboxane B2, aspirin dose and vascular events in blacks after recent cerebral infarction. Stroke 35(3), 727-730. (Pubitemid 38280849)
15. Campbell, C. L., & Steinhubl, S. R. (2005). Variability in response to aspirin: Do we understand the clinical relevance? J. Thromb. Haemost. 3(4), 665-669.
16. Campbell, J., Ridgway, H., & Carville, D. (2008). Plateletworks®. A novel point of care platelet function screen. Mol. Diag. Ther. 12(4), 253-258.
17. Catella, F., Healy, D., Lawson, J., & Fitzgerald, G. A. (1986). 11-dehydrothromboxane B2: A quantitative index of thromboxane A2 formation in the human circulation. Proc. Natl Acad. Sci. USA 83(16), 5861-5865.
18. Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., et al. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345 (25), 1809-1817.
19. Cattaneo, M. (2004). Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler. Thromb. Vasc. Biol. 24(11), 1980-1987.
20. Cattaneo, M. (2007). Laboratory detection of 'aspirin resistance': What test should we use (if any)? Eur. Heart J. 28(14), 1673-1675.
21. Chen, W., Lee, P., Ng, W., Tse, H. F., & Lau, C. P. (2004). Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol. 43(6), 1122-1126.
22. Chen, W. H., Cheng, X., Lee, P. Y., Ng, W., Kwok, J. Y., et al. (2007). Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am. J. Med. 120(7), 631-635.
23. Christie, D. J., Kottke-Marchant, K., & Gorman, R. T. (2007). Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 19(2), 104-110. (Pubitemid 351302380)
24. Cipollone, F., Mezzetti, A., Porreca, E., Di Febbo, C., Nutini, M., et al. (2002). Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia. Effects of statin therapy. Circulation 106(4), 399-402. (Pubitemid 34803680)
25. Cipollone, F., Ferri, C., Desideri, G., Paloscia, L., Materazzo, G., et al. (2003a). Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 108(22), 2776-2782. (Pubitemid 37498980)
26. Cipollone, F., Ganci, A., Greco, A., Panara, M. R., Pasquale, M., et al. (2003b). Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methylprednisolone in unstable angina. Circulation 107(1), 55-61. (Pubitemid 36070933)
27. Clappers, N., Van Oijen, M. G. H., Sundaresan, S., Brouwer, M. A., Te Morsche, R. H., et al. (2008). The C50T polymorphism of the cycloxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb. Haemost. 100(1), 70-75.
28. Conway, D. S. G., Pearce, L. A., Chin, B. S. P., Hart, R. G., Lip, G. Y., et al. (2003). Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 107(15), 3141-3145. (Pubitemid 36793082)
29. Cotter, G., Shemesh, E., Zehavi, M., Dinur, I., Rudnick, A., et al. (2004). Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin? Am. Heart J. 147(2), 293-300. (Pubitemid 38176831)
30. Cox, D., Maree, A. O., Dooley, M., Conroy, R., Byrne, M. F., & Fitzgerald, D. J. (2006). Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 37(8), 2153-2158. (Pubitemid 44309919)
31. Crescente, M., Di Castelnuovo, A., Iacoviello, L., Vermylen, J., Cerletti, C., & de Gaetano, G. (2008). Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb. Haemost. 99(1), 14-26.
32. De Gaetano, G.Collaborative group of the primary prevention project (PPP). (2001). Low dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Lancet 357(9250), 89-95.
33. de Lemos, J. A., Zirlik, A., Schonbeck, U., Varo, N., Murphy, S. A., Khera, A., et al. (2005). Associations between soluble CD40 ligand, atherosclerosis risk factors and subclinical atherosclerosis. Results from the Dallas heart study. Arterioscler. Thromb. Vasc. Biol. 25(10), 2192-2196.
34. Dichiara, J., Bliden, K. P., Tantry, U. S., Chaganti, S. K., Kreutz, R. P., et al. (2007a). Platelet function measured by VerifyNow® identifies generalised high platelet reactivity in aspirin treated patients. Platelets 18(6), 414-423. (Pubitemid 47347051)
35. DiChiara, J., Bliden, K. P., Tantry, U. S., Hamed, M. S., Antonino, M. J., et al. (2007b). The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: An analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56(12), 3014-3019. (Pubitemid 350223637)
36. Dippel, D. W. J., van Kooten, F., Leebeek, F. W. G., van Vliet, H. H., Mehicevic, A., Li, S. S., & Koudstaal, P. J. (2004). What is the lowest dose of aspirin for maximum suppression of in-vivo thromboxane production after a transient ischemic attack or ischemic stroke? Cerebrovasc. Dis. 17(4), 296-302. (Pubitemid 38621543)
37. Eikelboom, J. W., Hirsh, J., Weitz, J. I., Johnston, M., Yi, Q., & Yusuf, S. (2002). Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105(14), 1650-1655. (Pubitemid 34298607)
38. Eikelboom, J. W., Hankey, G. J., Thom, J., Claxton, A., Yi, Q., Gilmore, G., et al. (2005). Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: A randomised crossover trial. J. Thromb. Haemost. 3(12), 2649-2655.
39. Eikelboom, J. W., Hankey, G. J., Thom, J., Bhatt, D. L., Steg, P. G., Montalescot, G., et al. (2008). Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid. Determinants and effect on cardiovascular risks. Circulation 118(17), 1705-1712.
40. Evangelista, V., Manarini, S., Di Santo, A., Capone, M. L., Ricciotti, E., Di Francesco, L., et al. (2006). De novo synthesis of cyclooxygenase 1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ. Res. 98(5), 93-95.
41. Faraday, N., Becker, D. M., Yanek, L. R., Herrera-Galeano, J. E., Segal, J. B., Moy, T. F., et al. (2006). Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am. J. Cardiol. 98(6), 774-779.
42. Faraday, N., Yanek, L. R., Mathias, R., Herrera-Galeano, J. E., Vaidya, D., Moy, T. F., et al. (2007). Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115(19), 2490-2496. (Pubitemid 46763222)
43. Ferro, D., Loffredo, L., Polimeni, L., Fimognari, F., Villari, P., Pignatelli, P., et al. (2007). Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler. Thromb. Vasc. Biol. 27(12), 2763-2768.
44. Fitzgerald, G. A., Oates, J. A., Hawiger, J., Maas, R. L., Roberts, L. J., II, Lawson, J. A., & Brash, A. R. (1983). Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest. 71 (3), 676-688.
45. Frelinger, A. L., Furman, M. I., Linden, M. D., Li, Y., Fox, M. L., Barnard, M. R., & Michelson, A. D. (2006). Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway. A 700-patient study of aspirin resistance. Circulation 113(25), 2888-2896. (Pubitemid 44297229)
46. Friend, M., Vucenik, I., & Miller, M. (2003). Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 326(7380), 82-83. (Pubitemid 36092290)
47. Garcia Rodriguez, L. A., Varas-Lorenzo, C., Maguire, A., & Gonzalez-Perez, A. (2004). Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109(24), 3000-3006. (Pubitemid 38808323)
48. Garlichs, C. D., Kozina, S., Fateh-Moghadam, S., Handschu, R., Tomandl, B., Stumpf, C., et al. (2003). Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 34(7), 1412-1418.
49. Geisler, T., Langer, H., Wydymus, M., Göhring, K., Zürn, C., Bigalke, B., et al. (2006). Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur. Heart J. 27(20), 2420-2425.
50. Gonzalez-Conejero, R., Rivera, J., Corral, J., Acuña, C., Guerrero, J. A., Vicente, V., et al. (2005). Biological assessment of aspirin efficacy on healthy individuals. Heterogeneous response or aspirin failure? Stroke 36(2), 276-280.
51. Goodman, T., Ferro, A., & Sharma, P. (2008). Pharmacogenetics of aspirin resistance: A comprehensive systematic review. Br. J. Clin. Pharmacol. 66(2), 222-232.
52. Gum, P. A., Kattke-Marchant, K., Poggio, E. D., Gurm, H., Welsh, P. A., Brooks, L., et al. (2001). Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 88(3), 230-235.
53. Gum, P. A., Kottke-Marchant, K., Welsh, P. A., White, J., & Topol, E. J. (2003). A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 41(6), 961-965.
54. Gurbel, P. A., Becker, R. C., Mann, K. G., Steinhubl, S. R., & Michelson, A. D. (2007). Platelet function monitoring in patients with coronary artery disease. J. Am. Coll. Cardiol. 50(19), 1822-1834.
55. Hankey, G. J., & Eikelboom, J. W. (2006). Aspirin resistance. Lancet 2006(9510), 606-616.
56. Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., et al. (1998). Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351(9118), 1755-1762. (Pubitemid 28269185)
57. Harrison, P. (2000). Progress in the assessment of platelet function. Br. J. Haematol. 111(3), 733-744.
58. Harrison, P., Segal, H., Blasbery, K., Furtado, C., Silver, L., & Rothwell, P. M. (2005). Screening for aspirin responsiveness after transient ischemic attack and stroke. Comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36(5), 1001-1005.
59. Harrison, P., Segal, H., Silver, L., Syed, A., Cuthbertson, F. C., & Rothwell, P. M. (2008). Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 19(2), 119-124. (Pubitemid 351302375)
60. Hart, R. G., Leonard, A. D., Talbert, R. L., Pearce, L. A., Cornell, E., Bovill, E., & Feinberg, W. M. (2003). Aspirin dosage and thromboxane synthesis in patientswith vascular diseases. Pharmacotherapy 23(5), 579-584. (Pubitemid 36539038)
61. Heeschen, C., Dimmeler, S., Hamm, C. W., van den Brand, M. J., Boersma, E., Zeiher, A. M., et al. (2003). Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 348 (12), 1104-1111.
62. Helgason, C. M., Bolin, K. M., Hoff, J. A., Winkler, S. R., Mangat, A., Tortorice, K. L., & Brace, L. D. (1994). Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25(12), 2331-2336. (Pubitemid 24359298)
63. Ho, P. M., Spertus, J. A., Masoudi, F. A., Reid, K. J., Peterson, E. D., Magid, D. J., et al. (2006). Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch. Intern. Med. 166(17), 1842-1847.
64. Hocher, B., Liefeldt, L., Quaschning, T., Kalk, P., Ziebig, R., Godes, M., et al. (2007). Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis. J. Am. Soc. Nephrol. 18(4), 1323-1330.
65. Homoncik, M., Jilma, B., Hergovich, N., Stohlawetz, P., Panzer, S., & Speiser, W. (2000). Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyser PFA-100. Thromb. Haemost. 83(2), 316-321.
66. Hovens, M. M. C., Snoep, J. D., Eikenboom, J. C. J., van der Bom, J. G., Mertens, B. J., & Huisman, M. V. (2007a). Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review. Am. Heart J. 153(2), 175-181.
67. Hovens, M. M. C., Snoep, J. D., Groeneveld, Y., Tamsma, J. T., Eikenboom, J. C., & Huisman, M. V. (2007b). High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict ex vivo aspirin responsiveness in patients with type 2 diabetes. J. Thromb. Haemost. 5(7), 1562-1564.
68. Ikonomidis, I., Lekakis, J., Vamvakou, G., Andreotti, F., & Nihoyannopoulos, P. (2005). Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment. Am. Heart J. 149(5), 832-839.
69. Ivandic, B. T., Giannitsis, E., Schlick, P., Staritz, P., Katus, H. A., & Hohlfeld, T. (2007a). Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin. Chem. 53(4), 614-619.
70. Ivandic, B. T., Spanuth, E., Haase, D., Lestin, H. G., & Katus, H. A. (2007b). Increased plasma concentration of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin. Chem. 53(7), 1231-1234.
71. Karepov, V., Tolpina, G., Kuliczkowski, W., & Serebruany, V. (2008). Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. Cerebrovasc. Dis. 26(3), 272-276.
72. Karon, B. S., Wockenfus, A., Scott, R., Hartman, S. J., McConnell, J. P., Santrach, P. J., & Jaffe, A. S. (2008). Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. Clin. Chem. 54(6), 1060-1065.
73. Kinlay, S., Schwartz, G. G., Olsson, A. G., Rifai, N., Sasiela, W. J., Szarek, M., et al. (2004). Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study. Circulation 110(4), 386-391. (Pubitemid 38993846)
74. Krasopoulos, G., Brister, S. J., Beattie, W. S., & Buchanan, M. R. (2008). Aspirin "resistance" and risk of cardiovascular morbidity: A systematic review and metaanalysis. BMJ 336(7637), 195-198. (Pubitemid 351212675)
75. Kuliczkowski, W., Kobusiak-Prokopowicz, M., Prajs, I., Karolko, B., & Mazurek, W. (2007). Aspirin failure course during exercise and its connection with soluble CD40L. Thromb. Res. 119(6), 679-686.
76. Kurrelmeyer, K., Becker, L., Becker, D., Yanek, L., Goldschmidt-Clermont, P., & Bray, P. F. (2003). Platelet hyperreactivity in women from families with premature atherosclerosis. JAMWA 58(4), 272-277.
77. Kurth, T., Glynn, R. J., Walker, A. M., Chan, K. A., Buring, J. E., Hennekens, C. H., Gaziano, J. M. (2003). Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 108(10), 1191-1195. (Pubitemid 37099986)
78. Lee, K. W., Blann, A. D., & Lip, G. Y. H. (2005). Plasma markers of endothelial damage/ dysfunction, inflammation and thrombogenesis in relation to TIMI risk stratification in acute coronary syndromes. Thromb. Haemost. 94(5), 1077-1083.
79. Lennon, M. J., Gibbs, N. M., Weightman, W. M., McGuire, D., & Michalopoulos, N. (2004). A comparison of Plateletworks® and Platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J. Cardiovasc. Anaes 18(2), 136-140. (Pubitemid 38506856)
80. Lepantalo, A., Mikkelson, J., Resendiz, J. C., Viiri, L., Backman, J. T., Kankuri, E., et al. (2006). Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease. Thromb. Haemost. 95(2), 253-259.
81. Lev, E. I., Patel, R. T., Maresh, K. J., Guthikonda, S., Granada, J., DeLao, T., et al. (2006). Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. The role of dual drug resistance. J. Am. Coll. Cardiol. 47(1), 27-33.
82. Lev, E. I., Patel, R. T., Guthikonda, S., Lopez, D., Bray, P. F., & Kleiman, N. S. (2007). Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb. Res. 119(3), 355-360.
83. Lim, H. S., Blann, A. D., & Lip, G. Y. H. (2004). Soluble CD40 ligand, soluble P-selectin, interleukin-6 and tissue factor in diabetes mellitus. Relationships to cardiovascular disease and risk factor intervention. Circulation 109(21), 2524-2528.
84. Lim, E., Carballo, S., Cornelissen, J., Ali, Z. A., Grignani, R., Bellm, S., & Large, S. (2007). Dose related efficacy of aspirin after coronary surgery in patients with P1 (A2) polymorphism (NCT00262275). Ann. Thorac. Surg. 83(1), 134-138.
85. Lip, G. Y. H., Foster, W., & Blann, A. D. (2005). Plasma von Willebrand factor levels and surrogates of atherosclerosis. J. Thromb. Haemost. 3(4), 659-661.
86. Lordkipanidze, M., Pharand, C., Schampaert, E., Turgeon, J., Palisaitis, D. A., & Diodati, J. G. (2007). A comparison of sixmajor platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart J. 28 (14), 1702-1708.
87. MacDonald, T. M., Wei, L. (2003). Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 357(9357), 573-574. (Pubitemid 36207477)
88. MacDonald, T. M., & Wei, L. (2006). Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen? Basic Clin. Pharmacol. Toxicol. 98(3), 275-280.
89. Malarstig, A., Lindahl, B., Wallentin, L., & Siegbahn, A. (2006). Soluble CD40L levels are regulated by the-3459 ANG polymorphism and predict myocardial infarction and efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler. Thromb. Vasc. Biol. 26(7), 1667-1673.
90. Marcucci, R., Paniccia, R., Antonucci, E., Poli, S., Gori, A. M., Valente, S., et al. (2007). Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb. Haemost. 98(4), 844-851.
91. Mason, P. J., Jacobs, A. K., & Freedman, J. E. (2005). Aspirin resistance and atherothrombotic disease. J. Am. Coll. Cardiol. 46(6), 986-983.
92. Mateos-Caceres, P. J., Garcia-Mendez, A., Farre, A. L., Macaya, C., Núñez, A., Gómez, J., et al. (2004). Proteomic analysis of plasma from patients during an acute coronary syndrome. J. Am. Coll. Cardiol. 44(8), 1578-1583.
93. Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Bienart, R., Goldenberg, I., et al. (2004). Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109(25), 3171-3175.
94. McAdam BF, Byrne D, Morrow JD, Oates JA. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation 112 (7), 1024-1029
95. McGlasson, D. L., & Fritsma, G. A. (2008). Comparison of four laboratory methods to assess aspirin sensitivity. Blood Coagul. Fibrinolysis 19(2), 120-123. (Pubitemid 351252989)
96. McNicol, A., & Israels, S. J. (2003). Platelets and anti-platelet therapy. J. Pharmacol. Sci. 93(4), 381-396.
97. Michelson, A. D. (2004). Platelet function testing in cardiovascular diseases. Circulation 110(19), e489-e493.
98. Morange, P. E., Simon, C., Alessi, M. C., Luc, G., Arveiler, D., Ferrieres, J., et al. (2004). Endothelial cell markers and the risk of coronary heart disease. The prospective epidemiological study of myocardial infarction (PRIME) study. Circulation 109(11), 1343-1348.
99. Mortensen, J., Poulsen, T. S., Grove, E. L., Refsgaard, J., Nielsen, H. L., Pedersen, S. B., et al. (2008). Monitoring aspirin therapy with the Platelet Function Analyser-100. Scand. J. Clin. Lab. Invest. 68(8), 786-792.
100. Muir, A. R., McMullin, M. F., Patterson, C., & McKeown, P. P. (2009). Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 95(15), 1225-1229.
101. Nannizzi-Alaimo, L., Rubenstein, M. H., Alves, V. L., Leong, G. Y., Phillips, D. R., & Gold, H. K. (2002). Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 105(24), 2849-2854.
102. Nicholson, N., Panzer-Knodle, S., Haas, N., Taite, B. B., Szalony, J. A., Page, J. D., et al. (1998). Assessment of platelet function assays. Am. Heart J. 135(5 pt 2 suppl), S170-S178.
103. Ohmori, T., Yatomi, Y., Nonaka, T., Kobayashi, Y., Madoiwa, S., Mimuro, J., et al. (2006). Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: Involvement of other signalling pathway(s) in cardiovascular events of aspirin-treated patients. J. Thromb. Haemost. 4(6), 1271-1278.
104. Pamukcu, B. (2007). A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests and its clinical outcomes. J. Thromb. Thrombolysis 23(3), 213-222.
105. Pamukcu, B., Oflaz, H., & Nisanci, Y. (2005). The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am. Heart J. 149(4), 675-680.
106. Pamukcu, B., Oflaz, H., Oncul, A., Umman, B., Mercanoglu, F., Ozcan, M., et al. (2006). The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J. Thromb. Thrombolysis 22(2), 103-110. (Pubitemid 44473559)
107. Pamukcu, B., Oflaz, H., Onur, I., Midilli, K., Yilmaz, G., Yilmaz, E., & Nisanci, Y. (2008). Relationship between the serum sCD40L level and aspirin resistant platelet aggregation in patients with stable coronary artery disease. Circ. J. 72(1), 61-66. (Pubitemid 351413328)
108. Paniccia, R., Antonucci, E., Gori, A. M., Marcucci, R., Poli, S., Romano, E., et al. (2007). Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am. J. Clin. Pathol. 128(1), 143-149.
109. Paniccia, R., Antonucci, E., Maggini, N., Romano, E., Gori, A. M., Marcucci, R., et al. (2009). Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am. J. Clin. Pathol. 131(6), 834-842.
110. Paramo, J. A., Belqui, O., Colina, I., Diez, J., & Orbe, J. (2005). Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects. J. Thromb. Haemost. 3(4), 662-664.
111. Patrignani, P. (2003). Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb. Res. 110(5-6), 281-286.
112. Patrignani, P., Filabozzi, P., & Patrono, C. (1982). Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69, 1366-1372.
113. Perneby, C., Haken Wallen, N., Rooney, C., Fitzgerald, D., & Hjemdahl, P. (2006). Doseand time-dependent antiplatelet effects of aspirin. Thromb. Haemost. 95(4), 652-658.
114. Pouliot, M., Gilbert, C., Borgeat, P., Poubelle, P. E., Bourgoin, S., Créminon, C., et al. (1998). Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-activated human neutrophils. FASEB J. 12(12), 1109-1123. (Pubitemid 28418941)
115. Poulsen, T. S., Jorgensen, B., Korsholm, L., Bjørn Licht, P., Haghfelt, T., & Mickley, H. (2007). Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb. Res. 119(5), 555-562.
116. Pulcinelli, F. M., Pignatelli, P., Celestini, A., Riondino, S., Gazzaniga, P. P., & Violi, F. (2004). Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J. Am. Coll. Cardiol. 43(6), 979-984.
117. Rand, M. L., Leung, R., & Packham, M. A. (2003). Platelet function assays. Transfus. Apher. Sci. 28(3), 307-317.
118. Reny, J. L., De Moerloose, P., Dauzat, M., & Fontana, P. (2008). Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A systematic review and meta-analysis. J. Thromb. Haemost. 6(3), 444-450.
119. Ridker, P. M., Cook, N. R., Lee, I. M., Gordon, D., Gaziano, J. M., Manson, J. E., et al. (2005). A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352(13), 1293-1304.
120. Riondino, S., Trifiro, E., Principessa, L., Mascioletti, S., Di Renzo, L., Gaudio, C., et al. (2008). Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production. Thromb. Res. 122(3), 359-365.
121. Roth, G. J., & Calverly, D. C. (1994). Aspirin, platelets and thrombosis: Theory and practice. Blood 83(4), 885-898. (Pubitemid 24058536)
122. Santilli, F., Davi, G., Consoli, A., Cipollone, F., Mezzetti, A., Falco, A., et al. (2006). Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 47(2), 391-397.
123. Santos, M. T., Valles, J., Aznar, J., Marcus, A. J., Broekman, M. J., & Safier, L. B. (1997). Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation 95(1), 63-68. (Pubitemid 27029944)
124. Schonbeck, U., & Libby, P. (2001). CD40 signalling and plaque instability. Circ. Res. 89 (12), 1092-1103.
125. Schonbeck, U., Gerdes, N., Varo, N., Reynolds, R. S., Horton, D. B., Bavendiek, U., et al. (2002). Oxidised low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 106(23), 2888-2893. (Pubitemid 35424737)
126. Schroeder, W. S., Ghobrial, L., & Gandhi, P. J. (2006). Possible mechanisms of drug-induced aspirin and clopidogrel resistance. J. Thromb. Thrombolysis 22(2), 139-150. (Pubitemid 44473565)
127. Schwartz, K. A., Schwartz, D. E., Barber, K., Reeves, M., & De Franco, A. C. (2008). Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J. Transl. Med. 6, 46.
128. Scirica, B. M., Morrow, D. A., Cannon, C. P., de Lemos, J. A., Murphy, S., Sabatine, M. S., et al. (2007). Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin. Chem. 53(10), 1800-1807.
129. Serebruany, V. L., Pokov, A. N., Malinin, A. I., O'Connor, C., Bhatt, D. L., Tanguay, J. F., et al. (2006). Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am. Heart J. 151(1), 92-99.
130. Smith, C. J., Fischer, T. H., Heavner, D. L., Rumple, M. A., Bowman, D. L., Brown, B. G., et al. (2001). Urinary thromboxane, prostacyclin, cortisol and 8-hydroxy-2′-deoxyguanosine in non-smokers exposed and not exposed to environmental tobacco smoke. Toxicol. Sci. 59(2), 316-323.
131. Snoep, J. D., Hovens, M. M. C., Eikenboom, J. C. J., van der Bom, J. G., & Huisman, M. V. (2007). Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch. Intern. Med. 167(15), 1593-1599.
132. Sobieraj-Teague, M., & Eikelboom, J. W. (2010). Point-of-care testing for assessment of adequacy of oral anti-platelet therapy in patients with cardiovascular disease. Future Cardiol. 6(3), 289-299.
133. Steinhubl, S. R., Bhatt, D. L., Brennan, D. M., Montalescot, G., Hankey, G. J., Eikelboom, J.W., et al. (2009). Aspirin to prevent cardiovascular disease: The association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann. Intern. Med. 150(6), 379-386.
134. Szczeklik, A., Musial, J., Undas, A., & Sanak, M. (2005). Aspirin resistance. J. Thromb. Haemost. 3(8), 1655-1662.
135. Takahashi, S., Ushida, M., Komine, R., Shimizu, A., Uchida, T., Ishihara, H., et al. (2007). Increased basal platelet activity, plasma adiponectin levels and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb. Res. 119(4), 517-524.
136. Takahashi, S., Ushida, M., Komine, R., Shimodaira, A., Uchida, T., Ishihara, H., et al. (2008). Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb. Res. 121(4), 509-517.
137. Tirnaksiz, E., Pamukcu, B., Oflaz, H., & Nisanci, Y. (2009). Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. J. Thromb. Thrombolysis 27(1), 24-28.
138. Undas, A., Brummel-Ziedins, K. E., & Mann, K. G. (2007). Antithrombotic properties of aspirin and resistance to aspirin: Beyond strictly antiplatelet actions. Blood 109(6), 2285-2292. (Pubitemid 46425865)
139. Valles, J., Santos, M. T., Aznar, J., Osa, A., Lago, A., Cosin, J., et al. (1998). Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality. The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 97(4), 350-355.
140. Valles, J., Santos, M. T., Fuset, M. P., Moscardo, A., Ruano, M., Perez, F., et al. (2007). Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am. J. Cardiol. 99(1), 19-25.
141. Varo, N., de Lemos, J. A., Libby, P., Morrow, D. A., Murphy, S. A., Nuzzo, R., et al. (2003a). Soluble CD40L. Risk prediction after acute coronary syndromes. Circulation 108(9), 1049-1052.
142. Varo, N., Vincent, D., Libby, P., Nuzzo, R., Calle-Pascual, A. L., Bernal, M. R., et al. (2003b). Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients. A novel target of the thiazolidinediones. Circulation 107(21), 2664-2669. (Pubitemid 36667238)
143. Vischer, U. M. (2006). Von Willebrand factor, endothelial dysfunction and cardiovascular disease. J. Thromb. Haemost. 4(6), 1186-1193.
144. von Pape, K. W., Strupp, G., Banzel, T., & Bahner, J. (2005). Effect of compliance and dosage adaption of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction. Thromb. Haemost. 94(4), 889-891.
145. Watala, C., Pluta, J., Golanski, J., Rozalski, M., Czyz, M., Trojanowski, Z., & Drzewoski, J. (2005). Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J. Mol. Med. 83(2), 148-158.
146. Weber, A. A., Przytulski, B., Schnaz, A., Hohlfeld, T., & Schrör, K. (2002). Towards a definition of aspirin resistance: A typological approach. Platelets 13(1), 37-40. (Pubitemid 34169586)
147. Wenaweser, P., Dorffler-Melly, J., Imboden, K., Windecker, S., Togni, M., Meier, B., et al. (2005). Stent thrombosis is associated with an impaired response to antiplatelet therapy. J. Am. Coll. Cardiol. 45(11), 1748-1752.
148. Weyrich, A. S., Schwertz, H., Kraiss, L. W., & Zimmerman, G. A. (2009). Protein synthesis by platelets: Historical and new perspectives. J. Thromb. Haemost. 7, 241-246.
149. Williams, M. S., Kickler, T. S., Vaidya, D., Ng'alla, L. S., & Bush, D. E. (2006). Evaluation of platelet function in aspirin treated patients with CAD. J. Thromb. Thrombolysis 21(3), 241-247.
150. Yamada, K., Hirayama, T., & Hasegawa, Y. (2007). Antiplatelet effect of losartan and telmisartan in patientswith ischemic stroke. J. Stroke Cerebrovasc. Dis. 16(5), 225-231.
151. Yip, H., Wu, C., Yang, C. H., Chang, H. W., Fang, C. Y., Hung, W. C., & Hang, C. L. (2005). Serial changes in circulating concentrations of soluble CD40 ligand and C-reactive protein in patients with unstable angina undergoing coronary stenting. Role of inflammatory mediators in predicting late restenosis. Circ. J. 69(8), 890-895.
152. Zimmermann, N., Wenk, A., Kim, U., Kienzle, P., Weber, A. A., Gams, E., et al. (2003). Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108(5), 542-547. (Pubitemid 36961167)
153. Zimmermann, N., Kurt, M., Wenk, A., Winter, J., Gams, E., & Hohlfeld, T. (2005). Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? Eur. J. Cardiothorac. Surg. 27(4), 606-610.